• Coumestrol Workflows for ER and Ferroptosis Studies

  2026-09-22

  Coumestrol combines nanomolar estrogen-receptor pharmacology with a distinct high-micromolar ferroptosis workflow in rheumatoid arthritis fibroblast-like synoviocytes. This guide translates the reference study into practical dosing, orthogonal assays, troubleshooting steps, and controls for nuclear receptor and inflammation research.

• RESTRICT-seq Maps Epigenetic Dependencies in SCC Resistance

  2026-09-22

  The RESTRICT-seq preprint introduces a time-gated CRISPR screening strategy for separating gene perturbation from later selection for squamous cell carcinoma resistance. Its findings identify epigenetic regulators that may sustain resistant states and provide a framework for connecting genetic screens with chemically testable vulnerabilities.

• Berberine Hydrochloride: Mechanisms & Bone Research

  2026-09-21

  Berberine hydrochloride is an isoquinoline alkaloid used in metabolic, antimicrobial, apoptosis, ferroptosis, and gut–bone research. Recent preclinical evidence links berberine-driven butyrate production and GPR41-associated tuft cell expansion with improved intestinal barrier and bone-immune homeostasis during estrogen deficiency.

• 7-dehydro Cholesterol: Applied Research Workflows

  2026-09-21

  7-dehydro Cholesterol connects DHCR7-dependent sterol flux with UVB-driven vitamin D3 formation, oxidation-sensitive lipid biology, and disease-model research. This practical guide shows how to build controlled workflows, interpret chemical versus genetic perturbations, and troubleshoot solubility, photoconversion, and phenotype variability.

• RISOTTO Study: Risedronate in RA-Associated GIO

  2026-09-20

  The RISOTTO trial evaluated sodium risedronate in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis, addressing a clinical evidence gap with a multicentre, randomized, placebo-controlled design. Risedronate produced a significant six-month increase in lumbar spine bone mineral density and was well tolerated, although hip outcomes and fracture efficacy require more cautious interpretation.

• MG-132 for Reliable Apoptosis Assays

  2026-09-19

  Learn how MG-132 (SKU A2585) can improve the design, interpretation, and reproducibility of proteasome-inhibition experiments. This scenario-based guide covers dose selection, controls, storage, cytotoxicity readouts, and vendor-selection criteria for biomedical laboratories.

• 1-myristoylglycerophosphocholine in Fibrosis Assays

  2026-09-18

  Use 1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, as a defined lysophospholipid challenge for separating epithelial lipid release from direct fibroblast activation. This workflow combines fresh-solution handling, conditioned-medium controls, dose-ranging, and pathway-focused readouts for more reproducible fibrosis and lipid signaling experiments.

• Brain-to-Spinal Control of Opioid Mechanical Pain

  2026-09-18

  The reference study identifies a brain-to-spinal lPBNMOR+→PVHDyn+→SDHKOR-GABA pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. Its combination of focal opioid challenges, sensory phenotyping, circuit mapping, and causal pathway manipulation provides a framework for separating mechanical from thermal opioid adaptations in pain mechanism research.

• Silymarin: Silybin A Workflows for Liver Research

  2026-09-17

  Build solvent-controlled Silybin A assays for oxidative stress reduction, inflammatory signaling, metabolic enzyme modulation, and liver injury models. A targeted CRISPRi obesity study adds a practical design principle: separate tissue targeting from downstream hepatic readouts rather than treating a complex metabolic phenotype as a single assay.

• HOBt: Mechanistic Precision for Translational Synthesis

  2026-09-17

  HOBt (1-Hydroxybenzotriazole) is more than a conventional coupling additive: its active-ester chemistry can help protect stereochemical fidelity, improve amide bond formation, and strengthen the connection between synthetic execution and translational decision-making. This article examines its role through a published glucagon receptor antagonist program and provides practical guidance for peptide and medicinal chemistry workflows.

• Cy3-UTP for Fluorescent RNA Workflows

  2026-09-16

  Cy3-UTP enables direct visualization of RNA made by in vitro transcription, from RNA nanostructure assembly to uptake and persistence assays. This guide translates a plant spray-induced gene-silencing study into practical labeling, imaging, quality-control, and troubleshooting workflows.

• ROS-Responsive LNPs for Tumor-Selective mRNA Delivery

  2026-09-16

  The reference study develops a combinatorial library of thioketal-containing, ROS-degradable lipid nanoparticles for preferential mRNA delivery to tumor cells. Its lead lipid, BAmP-TK-12, enabled delivery of DUF5 mRNA to deplete mutant RAS and suppress tumor growth, while also illustrating important constraints for translating ROS-responsive delivery into broader therapeutic settings.

• 4-Ethylphenyl Sulfate Research Workflows

  2026-09-15

  4-Ethylphenyl sulfate supports two complementary research paths: gut microbiota-brain interaction research and renal toxin or biomaterial adsorption assays. This guide converts its reported biology and physicochemical profile into practical workflows for LC-MS, behavioral studies, and PEO-surface screening.

• Cholesterol for mRNA-LNP Workflow Design

  2026-09-15

  Learn how to use Cholesterol as a controllable formulation variable in mRNA–lipid nanoparticle studies, from ethanol stock preparation through membrane and reporter assays. The workflow connects the principal sterol’s biophysical role with the localized p21 mRNA–LNP strategy reported for bladder cancer while clearly separating published findings from practical optimization recommendations.

• Trametinib (GSK1120212) Experimental Workflows

  2026-09-14

  Build reproducible MEK-ERK pathway experiments with Trametinib (GSK1120212), from DMSO stock preparation through phospho-ERK and viability readouts. The workflow emphasizes hypoxia-associated EGFR inhibitor resistance, B-RAF model selection, combination design, and practical troubleshooting.

8507 records 1/568 page Next 12345 下5页 Last page